Molecular genetics of medullary thyroid carcinoma: The quest for novel therapeutic targets

Journal of Molecular Endocrinology

Volumn 43, Issue 4, 2009, Pages 143-155

  Cerrato, Aniello ^a   De Falco, Valentina ^a   Santoro, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMIN; BETA CATENIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NEURTURIN; PERSEPHIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEIN RET; PROTEIN TYROSINE PHOSPHATASE; RAS PROTEIN; RETINOBLASTOMA PROTEIN; STAT PROTEIN; TYROSINE KINASE RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CANCER GENETICS; CELL ADHESION; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; GENETIC SCREENING; HUMAN; METASTASIS; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA;

ANIMALS; CARCINOMA, MEDULLARY; HUMANS; MICE; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 70450184514     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-09-0024     Document Type: Review

References (155)

1. Acton DS, Velthuyzen D, Lips CJ & Höppener JW 2000 Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 19 3121-3125. (Pubitemid 30438470)
2. Airaksinen MS & Saarma M 2002 The GDNF family: signalling, biological functions and therapeutic value. Nature Reviews. Neuroscience 3 383-394. (Pubitemid 135706635)
3. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J et al. 2007 A module of negative feedback regulators defines growth factor signaling. Nature Genetics 39 503-512.
4. Asai N, Fukuda T, Wu Z, Enomoto A, Pachnis V, Takahashi M & Costantini F 2006a Targeted mutation of serine 697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells. Development 133 4507-4516. (Pubitemid 46017825)
5. Asai N, Jijiwa M, Enomoto A, Kawai K, Maeda K, Ichiahara M, Murakumo Y & Takahashi M 2006b RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease. Pathology International 56 164-172.
6. Bai F, Pei XH, Pandolfi PP & Xiong Y 2006 p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. Molecular and Cellular Biology 26 4564-4576.
7. Basson MA, Akbulut S, Watson-Johnson J, Simon R, Carroll TJ, Shakya R, Gross I, Martin GR, Lufkin T, McMahon AP et al. 2005 Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Developmental Cell 8 229-239. (Pubitemid 40197739)
8. Baud V & Karin M 2009 Is NF-kB a good target for cancer therapy? Hopes and pitfalls Nature Reviews. Drug Discovery 8 33-40.
9. Bjornsti MA & Houghton PJ 2004 The TOR pathway: a target for cancer therapy. Nature Reviews. Cancer 4 335-348. (Pubitemid 38579480)
10. Bockhorn M, Frilling A, Kalinin V, Schröder S & Broelsch CE 2000 Absence of H- and K-ras oncogene mutations in sporadic medullary thyroid carcinoma. Experimental and Clinical Endocrinology and Diabetes 108 49-53. (Pubitemid 30160435)
11. Borrego S, Eng C, Sánchez B, Sáez ME, Navarro E & Antiñolo G 1998 Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. Journal of Clinical Endocrinology and Metabolism 83 3361-3364. (Pubitemid 28500986)
12. Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P et al. 1996 The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Molecular and Cellular Biology 16 2151-2163. (Pubitemid 26123736)
13. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A et al. 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 86 5658-5671.
14. Brembeck FH, Rosário M & Birchmeier W 2006 Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Current Opinion in Genetics and Development 16 51-59. (Pubitemid 43089612)
15. Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP et al. 2007 Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nature Genetics 39 1120-1126. (Pubitemid 47340658)
16. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A & Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research 15 7284-7290.
17. Carson-Walter EB, Smith DP, Ponder BA, Baylin SB & Nelkin BD 1998 Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells. Oncogene 17 367-376.
18. Cascon A, Cebrian A, Pollan M, Ruiz-Llorente S, Montero-Conde C, Leton R, Gutierrez R, Lesueur F, Milne RL, Gonzalez-Albarran O et al. 2005 Succinate dehydrogenase D variants do not constitute a risk factor for developing C cell hyperplasia or sporadic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 90 2127-2130.
19. Cassinelli G, Favini E, Degl'Innocenti D, Salvi A, De Petro G, Pierotti MA, Zunino F, Borrello MG & Lanzi C 2009 RET/PTC1- driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia 11 10-21.
20. Castellone MD, Carlomagno F, Salvatore G & Santoro M 2008 Receptor tyrosine kinase inhibitors in thyroid cancer. Best Practice and Research. Clinical Endocrinology and Metabolism 22 1023-1038.
21. Castellone MD, De Falco V, Rao DM, Bellelli R, Muthu M, Basolo F, Fusco A, Gutkind JS & Santoro M2009 The b-catenin axis integrates multiple signals downstream from RET/PTC and leads to cell proliferation. Cancer Research 69 1867-1876.
22. Cebrian A, Lesueur F, Martin S, Leyland J, Ahmed S, Luccarini C, Smith PL, Luben R, Whittaker J, Pharoah PD et al. 2005 Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 90 6268-6274. (Pubitemid 41606555)
23. Chiariello M, Visconti R, Carlomagno F, Melillo RM, Bucci C, de Franciscis V, Fox GM, Jing S, Coso OA, Gutkind JS et al. 1998 Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene 16 2435-2445. (Pubitemid 28258576)
24. Colucci-D'Amato GL, D'Alessio A, CalifanoD, Cali G, Rizzo C, Nitsch L, Santelli G & de Franciscis V 2000 Abrogation of nerve growth factorinduced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK. Journal of Biological Chemistry 275 19306-19314. (Pubitemid 30422904)
25. Coxon AB, Ward JM, Geradts J, Otterson GA, Zajac-Kaye M & Kaye FJ 1998 RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer. Oncogene 17 1625-1628. (Pubitemid 28472767)
26. Cranston AN & Ponder BA 2003 Modulation of medullary thyroid carcinoma penetrance suggests the presence of modifier genes in a RET transgenic mouse model. Cancer Research 63 4777-4780.
27. Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane H & Fagin JA 2008 RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Research 68 4183-4191.
28. D'Alessio A, Califano D, Incoronato M, Santelli G, Florio T, Schettini G, Carlomagno MS, Cerchia L & de Franciscis V 2003 The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants. Endocrinology 144 4298-4305. (Pubitemid 37204828)
29. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP & Baldwin AS 2008 Akt-dependent regulation of NF-kB is controlled by mTOR and Raptor in association with IKK. Genes and Development 22 1490-1500.
30. Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA & Pützer BM 2004 Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. Journal of the National Cancer Institute 96 1231-1239. (Pubitemid 39232714)
31. Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R, Barale R, Pacini F & Pinchera A 2004 RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. Journal of Clinical Endocrinology and Metabolism 89 3579-3584. (Pubitemid 38951937)
32. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L et al. 2007 RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. Journal of Clinical Endocrinology and Metabolism 92 4725-4729. (Pubitemid 350223450)
33. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F et al. 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. Journal of Clinical Endocrinology and Metabolism 93 682-687.
34. Encinas M, Crowder RJ, Milbrandt J & Johnson EM Jr 2004 Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival. Journal of Biological Chemistry 279 18262-18269.
35. Encinas M, Rozen EJ, Dolcet X, Jain S, Comella JX, Milbrandt J & Johnson EM Jr 2008 Analysis of Ret knockin mice reveals a critical role for IKKs, but not PI 3-K, in neurotrophic factor-induced survival of sympathetic neurons. Cell Death and Differentiation 15 1510-1521.
36. Ezzat S, Huang P, Dackiw A & Asa SL 2005 Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clinical Cancer Research 11 1336-1341. (Pubitemid 40175788)
37. Fagin JA 2005 Genetics of papillary thyroid cancer initiation: implications for therapy. Transactions of the American Clinical and Climatological Association 116 259-269.
38. Ferris RL & Simental AA Jr 2004 Molecular biology of primary hyperparathyroidism. Otolaryngologic Clinics of North America 37 819-831.
39. Franklin DS, Godfrey VL, O'Brien DA, Deng C & Xiong Y 2000 Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Molecular and Cellular Biology 20 6147-6158. (Pubitemid 30613062)
40. Fukuda T, Kiuchi K & Takahashi M 2002 Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase. Journal of Biological Chemistry 277 19114-19121. (Pubitemid 34952477)
41. Gagel FR & Marx SJ 2003 Multiple endocrine neoplasia. In Williams Textbook of Endocrinology, 10 edn, pp 1717-1762. Eds PR Larsen, H Kronenberg, S Melmed & K Polonsky. Philadelphia: Saunders, Elsevier Science.
42. Gallel P, Pallares J, Dolcet X, Llobet D, Eritja N, Santacana M, Yeramian A, Palomar-Asenjo V, Lagarda H, Mauricio D et al. 2008 Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Human Pathology 39 994-1001.
43. Gimm O, Greco A, Hoang-Vu C, Dralle H, Pierotti MA & Eng C 1999 Mutation analysis reveals novel sequence variants in NTRK1 in sporadic human medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 84 2784-2787. (Pubitemid 30642013)
44. Gimm O, Dziema H, Brown J, Hoang-Vu C, Hinze R, Dralle H, Mulligan LM & Eng C 2001a Over-representation of a germline variant in the gene encoding RET co-receptor GFRalpha-1 but not GFRalpha-2 or GFRalpha-3 in cases with sporadic medullary thyroid carcinoma. Oncogene 20 2161-2170. (Pubitemid 32424010)
45. Gimm O, Dziema H, Brown J, de la Puente A, Hoang-Vu C, Dralle H, Plass C & Eng C 2001b Mutation analysis of NTRK2 and NTRK3, encoding 2 tyrosine kinase receptors, in sporadic human medullary thyroid carcinoma reveals novel sequence variants. International Journal of Cancer 92 70-74. (Pubitemid 32187034)
46. Gorla L, Mondellini P, Cuccuru G, Miccichè F, Cassinelli G, Cremona M, Pierotti MA, Lanzi C & Bongarzone I 2009 Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements. Molecular Carcinogenesis 48 220-231.
47. Goutas N, Vlachodimitropoulos D, BoukaM, Lazaris AC, Nasioulas G & Gazouli M 2008 BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Research 28 305-308. (Pubitemid 351362917)
48. Gujral TS, van Veelen W, Richardson DS, Myers SM, Meens JA, Acton DS, Duñach M, Elliott BE, Höppener JW & Mulligan LM 2008 A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Research 68 1338-1346.
49. Hahn WC & Weinberg RA 2002 Modelling the molecular circuitry of cancer. Nature Reviews. Cancer 2 331-341.
50. Halilovic E & Solit DB 2008 Therapeutic strategies for inhibiting oncogenic BRAF signaling. Current Opinion in Pharmacology 8 419-426.
51. Harrison DJ, Hooper ML, Armstrong JF & Clarke AR 1995 Effects of heterozygosity for the Rb-1t19neo allele in the mouse. Oncogene 10 1615-1620.
52. Harvey M, Vogel H, Lee EY, Bradley A & Donehower LA 1995 Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Research 55 1146-1151.
53. Hasegawa T, Enomoto A, Kato T, Kawai K, Miyamoto R, Jijiwa M, Ichihara M, Ishida M, Asai N, Murakumo Y et al. 2008 Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice. Oncogene 27 5684-5695.
54. Hennige AM, Lammers R, Höppner W, Arlt D, Strack V, Teichmann R, Machicao F, Ullrich A, Häring HU & Kellerer M 2001 Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology 142 4441-4447. (Pubitemid 32907074)
55. Herfarth KK, Wick MR, Marshall HN, Gartner E, Lum S & Moley JF 1997 Absence of TP53 alterations in pheochromocytomas and medullary thyroid carcinomas. Genes, Chromosomes and Cancer 20 24-29. (Pubitemid 27377095)
56. Horie H, Yokogoshi Y, Tsuyuguchi M& Saito S 1995 Point mutations of ras and Gs alpha subunit genes in thyroid tumors. Japanese Journal of Cancer Research 86 737-742.
57. Huang SC, Torres-Cruz J, Pack SD, Koch CA, Vortmeyer AO, Mannan P, Lubensky IA, Gagel RF & Zhuang Z 2003 Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 88 459-463. (Pubitemid 36115202)
58. Iavarone C, Acunzo M, Carlomagno F, Catania A, Melillo RM, Carlomagno SM, Santoro M & Chiariello M 2006 Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. Journal of Biological Chemistry 281 10567-10576.
59. Iervolino A, Iuliano R, Trapasso F, Viglietto G, Melillo RM, Carlomagno F, Santoro M & Fusco A 2006 The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. Cancer Research 66 6280-6287.
60. Incoronato M, D'Alessio A, Paladino S, Zurzolo C, Carlomagno MS, Cerchia L & de Franciscis V 2004 The Shp-1 and Shp-2, tyrosine phosphatases, are recruited on cell membrane in two distinct molecular complexes including Ret oncogenes. Cellular Signalling 16 847-856. (Pubitemid 38534532)
61. Ishida M, Ichihara M, Mii S, Jijiwa M, Asai N, Enomoto A, Kato T, Majima A, Ping J, Murakumo Y et al. 2007 Sprouty2 regulates growth and differentiation of human neuroblastoma cells through RET tyrosine kinase. Cancer Research 98 815-821. (Pubitemid 46691817)
62. Jain S, Encinas M, Johnson EM Jr & Milbrandt J 2006 Critical and distinct roles for key RET tyrosine docking sites in renal development. Genes and Development 20 321-333. (Pubitemid 43200286)
63. Johnston D, Hatzis D & Sunday ME 1998 Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma. Oncogene 16 167-177. (Pubitemid 28045102)
64. Joshi PP, Kulkarni MV, Yu BK, Smith KR, Norton DL, Veelen W, Höppener JW & Franklin DS 2007 Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2ARET- mediated mitogenesis. Oncogene 26 554-570. (Pubitemid 46160969)
65. Kaelin WG Jr 2008 The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nature Reviews. Cancer 8 865-873.
66. Kawai K, Iwashita T, Murakami H, Hiraiwa N, Yoshiki A, Kusakabe M, Ono K, Iida K, Nakayama A & Takahashi M 2000 Tissue-specific carcinogenesis in transgenic mice expressing the RET protooncogene with a multiple endocrine neoplasia type 2A mutation. Cancer Research 60 5254-5260. (Pubitemid 30739786)
67. Kedzia C, Lacroix L, Ameur N, Ragot T, Kelly PA, Caillou B & Binart N 2005 Medullary thyroid carcinoma arises in the absence of prolactin signaling. Cancer Research 65 8497-8503. (Pubitemid 41330618)
68. Khosla S, Patel VM, Hay ID, Schaid DJ, Grant CS, van Heerden JA & Thibodeau SN 1991 Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. Journal of Clinical Investigation 87 1691-1699.
69. Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibáñez CF & McDonald NQ 2006 Structure and chemical inhibition of the RET tyrosine kinase domain. Journal of Biological Chemistry 281 33577-33587. (Pubitemid 46036738)
70. Koch CA, Brouwers FM, Vortmeyer AO, Tannapfel A, Libutti SK, Zhuang Z, Pacak K, Neumann HP & Paschke R 2006 Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer 6 131. (Pubitemid 43970757)
71. Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M & Takahashi M 2005 The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Research 96 143-148. (Pubitemid 40575914)
72. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 6 292-306.
73. Kondoh K & Nishida E 2007 Regulation of MAP kinases by MAP kinase phosphatases. Biochimica et Biophysica Acta 1773 1227-1237. (Pubitemid 47125976)
74. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE & Evans DB 2005 RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15 531-544.
75. Kucherlapati MH, Nguyen AA, Bronson RT & Kucherlapati RS 2006 Inactivation of conditional Rb by Villin-Cre leads to aggressive tumors outside the gastrointestinal tract. Cancer Research 66 3576-3583.
76. Kunnimalaiyaan M, Ndiaye M & Chen H 2006a Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 140 1009-1014.
77. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA & Chen H 2006b Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. Journal of Biological Chemistry 281 39819-39830. (Pubitemid 46041785)
78. Lanigan TM, DeRaad SK & Russo AF 1998 Requirement of the MASH- 1 transcription factor for neuroendocrine differentiation of thyroid C cells. Journal of Neurobiology 34 126-134.
79. Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA & Dynlacht BD 2002 E2F4 loss suppresses tumorigenesis in Rb mutant mice. Cancer Cell 2 463-472. (Pubitemid 41043951)
80. Lesueur F, Cebrian A, Robledo M, Niccoli-Sire P, Svensson KA, Pinson S, Leyland J, Whittaker J, Pharoah PD & Ponder BA 2006 Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Research 66 1177-1180. (Pubitemid 43165988)
81. Levine RL & Gilliland DG 2008 Myeloproliferative disorders. Blood 112 2190-2198.
82. Lima J, Teixeira-Gomes J, Soares P, Máximo V, Honavar M, Williams D & Sobrinho-Simões M 2003 Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. Journal of Clinical Endocrinology and Metabolism 88 4932-4937. (Pubitemid 37357546)
83. Lindahl M, Poteryaev D, Yu L, Arumae U, Timmusk T, Bongarzone I, Aiello A, Pierotti MA, Airaksinen MS & Saarma M 2001 Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells. Journal of Biological Chemistry 276 9344-9351. (Pubitemid 37385521)
84. Lindfors PH, Lindahl M, Rossi J, Saarma M & Airaksinen MS 2006 Ablation of persephin receptor glial cell line-derived neurotrophic factor family receptor alpha4 impairs thyroid calcitonin production in young mice. Endocrinology 147 2237-2244.
85. Lo TL, Fong CW, Yusoff P, McKie AB, Chua MS, Leung HY & Guy GR 2006 Sprouty and cancer: the first terms report. Cancer Letters 242 141-150. (Pubitemid 44515046)
86. Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, Böhm BO & Schmid RM 2001 Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Research 61 4526-4535. (Pubitemid 32685784)
87. Luo W, Wickramasinghe SR, Savitt JM, Griffin JW, Dawson TM & Ginty DD 2007 A hierarchical NGF signaling cascade controls Ret-dependent and Ret-independent events during development of nonpeptidergic DRG neurons. Neuron 54 739-754. (Pubitemid 46843519)
88. Machens A & Dralle H 2007 Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World Journal of Surgery 31 957-968. (Pubitemid 46716774)
89. Maher ER & Eng C 2002 The pressure rises: update on the genetics of phaeochromocytoma. Human Molecular Genetics 11 2347-2354. (Pubitemid 35174697)
90. Marsh DJ, Zheng Z, Arnold A, Andrew SD, Learoyd D, Frilling A, Komminoth P, Neumann HP, Ponder BA, Rollins BJ et al. 1997 Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 82 3025-3028. (Pubitemid 27385666)
91. Marsh DJ, Theodosopoulos G, Martin-Schulte K, Richardson AL, Philips J, Röher HD, Delbridge L & Robinson BG 2003 Genomewide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 88 1866-1872. (Pubitemid 36623416)
92. Marx SJ 2005 Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nature Reviews. Cancer 5 367-375. (Pubitemid 40637828)
93. Mathew CG, Smith BA, Thorpe K, Wong Z, Royle NJ, Jeffreys AJ & Ponder BA 1987 Deletion of genes on chromosome 1 in endocrine neoplasia. Nature 328 524-526. (Pubitemid 17098352)
94. Matias-Guiu X, Bussolati G, DeLellis R, Kaserer K, Moley JF, Williams ED, Gagel RF, Baloch Z & Arbores-Saavedra J 2004 Medullary thyroid carcinoma. In World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Endocrine Organs, pp 86-91. Ed RA DeLellis et al.. Geneva: WHO Press.
95. McGregor LM, McCune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD, Ball DW, Baylin SB & Nelkin BD 1999 Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. PNAS 96 4540-4545.
96. Michiels FM, Chappuis S, Caillou B, Pasini A, Talbot M, Monier R, Lenoir GM, Feunteun J & Billaud M 1997 Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. PNAS 94 3330-3335. (Pubitemid 27157311)
97. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA et al. 2004 Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5 221-230. (Pubitemid 38402114)
98. Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S & Mitsiades N 2006a Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. Journal of Clinical Endocrinology and Metabolism 91 3662-3666. (Pubitemid 44402152)
99. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB & Mitsiades N 2006b Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. Journal of Clinical Endocrinology and Metabolism 91 4013-4021. (Pubitemid 44536879)
100. Moley JF, Brother MB, Wells SA, Spengler BA, Biedler JL & Brodeur GM 1991 Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers. Cancer Research 51 1596-1599.
101. MontaniM, Schmitt AM, Schmid S, Locher T, Saremaslani P, Heitz PU, Komminoth P & Perren A 2005 No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma. Endocrine-Related Cancer 12 1011-1016. (Pubitemid 41815793)
102. Montero-Conde C, Ruiz-Llorente S, González-Albarran O, Landa I, Pita G, Milne R, Leskelä S, López-Jiménez E, Urioste M, Letón R et al. 2007 Identification of a candidate chromosomal region using a SNP linkage panel suggests a second locus responsible for non-RET MEN2 families. Hormone Research 68 6-7.
103. Mulligan LM, Gardner E, Smith BA, Mathew CG & Ponder BA 1993 Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2. Genes, Chromosomes and Cancer 6 166-177. (Pubitemid 23079559)
104. Nakagawa T, Mabry M, de Bustros A, Ihle JN, Nelkin BD & Baylin SB 1987 Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells. PNAS 84 5923-5927. (Pubitemid 17130421)
105. Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S et al. 2001 Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype- genotype relationship in a large series of patients. Journal of Clinical Endocrinology and Metabolism 86 3746-3753. (Pubitemid 32755971)
106. Paes JE & Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinology and Metabolism Clinics of North America 37 375-387 (viii-ix).
107. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C & Koff A 1999 p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. PNAS 96 6382-6387. (Pubitemid 29256674)
108. Parthasarathy R, Cote GJ & Gagel RF 1999 Hammerhead ribozymemediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Research 59 3911-3914. (Pubitemid 29393551)
109. Pavelić K, Dedivitis RA, Kapitanović S, Cacev T, Guirado CR, Danić D, Radosević S, Brkić K, Pegan B, Krizanac S et al. 2006 Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions. Mutation Research 599 45-57. (Pubitemid 44043170)
110. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J & Atkinson MJ 2006 Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. PNAS 103 15558-15563. (Pubitemid 44625631)
111. Pierchala BA, Tsui CC, Milbrandt J & Johnson EM 2007 NGF augments the autophosphorylation of Ret via inhibition of ubiquitindependent degradation. Journal of Neurochemistry 100 1169-1176. (Pubitemid 46246395)
112. Pierotti MA & Greco A 2006 Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Letters 232 90-98.
113. Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH et al. 2005 RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Research 65 1729-1737. (Pubitemid 40478598)
114. Plaza-Menacho I, van der Sluis T, Hollema H, Gimm O, Buys CH, Magee AI, Isacke CM, Hofstra RM & Eggen BJ 2007 Ras/ERK1/ 2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. Journal of Biological Chemistry 282 6415-6424. (Pubitemid 47100884)
115. Qiao S, Iwashita T, Furukawa T, Yamamoto M, Sobue G & Takahashi M 2001 Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins. Journal of Biological Chemistry 276 9460-9467. (Pubitemid 37385535)
116. Rangarajan A & Weinberg RA 2003 Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nature Reviews. Cancer 3 952-959. (Pubitemid 37500180)
117. Robledo M, Gil L, Pollán M, Cebrián A, Ruíz S, Azañedo M, Benitez J, Menárguez J & Rojas JM 2003 Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Research 63 1814-1817.
118. Ruiz-Llorente S, Montero-Conde C, Milne RL, Moya CM, Cebrián A, Letón R, Cascón A, Mercadillo F, Landa I, Borrego S et al. 2007 Medullary Thyroid Carcinoma Clinical Group. Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma. Cancer Research 67 9561-9567.
119. Salmena L, Carracedo A & Pandolfi PP 2008 Tenets of PTEN tumor suppression. Cell 133 403-414.
120. Santoro M & Carlomagno F 2006 Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice. Endocrinology and Metabolism 2 42-52.
121. Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C & Dammann R 2006 CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16 633-642. (Pubitemid 44246258)
122. Schlumberger M, Carlomagno F, Baudin E, Bidart JM & Santoro M 2008 New therapeutic approaches to treat medullary thyroid carcinoma. Nature Clinical Practice. Endocrinology and Metabolism 4 22-32. (Pubitemid 350291115)
123. Schubbert S, Shannon K & Bollag G 2007 Hyperactive Ras in developmental disorders and cancer. Nature Reviews. Cancer 7 295-308. (Pubitemid 46480970)
124. Schulz N, Propst F, Rosenberg MP, Linnoila RI, Paules RS, Kovatch R, Ogiso Y & Vande Woude G 1992 Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: amodel for the human multiple endocrine neoplasia type 2 syndrome. Cancer Research 52 450-455.
125. Segouffin-Cariou C & Billaud M 2000 Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. Journal of Biological Chemistry 275 3568-3576. (Pubitemid 30083066)
126. Sheikh HA, Tometsko M, Niehouse L, Aldeeb D, Swalsky P, Finkelstein S, Barnes EL & Hunt JL 2004 Molecular genotyping of medullary thyroid carcinoma can predict tumor recurrence. American Journal of Surgical Pathology 28 101-106. (Pubitemid 38031628)
127. Sherman SI 2008 Early clinical studies of novel therapies for thyroid cancers. Endocrinology and Metabolism Clinics of North America 37 511-524 (xi).
128. Sipple JH 1961 The association of pheochromocytoma with carcinoma of the thyroid gland. American Journal of Medicine 31 163-166.
129. Sjöblom T 2008 Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human proteincoding genes. Current Opinion in Oncology 20 66-71. (Pubitemid 350190983)
130. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK & Wells SA Jr 2005 Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. New England Journal of Medicine 353 1105-1113. (Pubitemid 41317433)
131. Smith-Hicks CL, Sizer KC, Powers JF, Tischler AS & Costantini F 2000 C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. EMBO Journal 19 612-622. (Pubitemid 30093734)
132. Sobrinho-Simões M, Máximo V, Rocha AS, Trovisco V, Castro P, Preto A, Lima J & Soares P 2008 Intragenic mutations in thyroid cancer. Endocrinology and Metabolism Clinics of North America 37 333-362 (viii).
133. van Staveren WC, Solís DW, Delys L, Venet D, Cappello M, Andry G, Dumont JE, Libert F, Detours V & Maenhaut C 2006 Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. PNAS 103 413-418. (Pubitemid 43122415)
134. Takahashi C, Contreras B, Iwanaga T, Takegami Y, Bakker A, Bronson RT, Noda M, Loda M, Hunt JL & Ewen ME 2006 Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. Nature Genetics 38 118-123. (Pubitemid 43011892)
135. Taketomi T, Yoshiga D, Taniguchi K, Kobayashi T, Nonami A, Kato R, Sasaki M, Sasaki A, Ishibashi H, Moriyama M et al. 2005 Loss of mammalian Sprouty2 leads to enteric neuronal hyperplasia and esophageal achalasia. Nature Neuroscience 8 855-857.
136. Trimarchi JM & Lees JA 2002 Sibling rivalry in the E2F family. Nature Reviews. Molecular Cell Biology 3 11-20.
137. Tsui-Pierchala BA, Milbrandt J & Johnson EM Jr 2002 NGF utilizes c-Ret via a novel GFL-independent, inter-RTK signaling mechanism to maintain the trophic status of mature sympathetic neurons. Neuron 33 261-273. (Pubitemid 34127758)
138. Vanhorne JB, Andrew SD, Harrison KJ, Taylor SA, Thomas B, McDonald TJ, Ainsworth PJ & Mulligan LM 2005 A model for GFR alpha 4 function and a potential modifying role in multiple endocrine neoplasia 2. Oncogene 24 1091-1097. (Pubitemid 40313886)
139. van Veelen W, van Gasteren CJ, Acton DS, Franklin DS, Berger R, Lips CJ & Höppener JW 2008 Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development. Cancer Research 68 1329-1337. (Pubitemid 351346839)
140. van Veelen W, Klompmaker R, Gloerich M, van Gasteren CJ, Kalkhoven E, Berger R, Lips CJ, Medema RH, Höppener JW & Acton DS 2009 P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development. International Journal of Cancer 124 339-345.
141. Weber F & Eng C 2005 Editorial: germline variants within RET: clinical utility or scientific playtoy? Journal of Clinical Endocrinology and Metabolism 90 6334-6336.
142. Wellbrock C, Karasarides M & Marais R 2004 The RAF proteins take centre stage. Nature Reviews. Molecular Cell Biology 5 875-885.
143. Wells SA & Nevins JR 2004 Evolving strategies for targeted cancer therapy - past, present, and future. Journal of the National Cancer Institute 96 980-981. (Pubitemid 39162632)
144. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT & Jacks T 1994 Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genetics 7 480-484. (Pubitemid 24308333)
145. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J et al. 2007 The genomic landscapes of human breast and colorectal cancers. Science 318 1108-1113. (Pubitemid 350134889)
146. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D & Xing M 2005 Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. Journal of Clinical Endocrinology and Metabolism 90 4688-4693. (Pubitemid 41159359)
147. XingM2005 BRAF mutation in thyroid cancer. Endocrine-Related Cancer 12 245-262.
148. Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E & Jacks T 1998 Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-) mice. Nature Genetics 18 360-364. (Pubitemid 28158165)
149. Yang KP, Samaan NA, Liang YF & Castillo SG 1992 Role of insulin-like growth factor-I in the autocrine regulation of cell growth in TT human medullary thyroid carcinoma cells. Henry Ford Hospital Medical Journal 40 293-295.
150. Ye L, Santarpia L, Cote GJ, El-Naggar AK & Gagel RF 2008 High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 93 4367-4372. (Pubitemid 352789533)
151. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S & Itakura M 1992 Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Research 52 5061-5064.
152. Yuan TL & Cantley LC 2008 PI3K pathway alterations in cancer: variations on a theme. Oncogene 27 5497-5510.
153. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A & degli Uberti EC 2005 SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma. Endocrinology 146 2692-2698. (Pubitemid 40695572)
154. Zbuk KM & Eng C 2007 Cancer phenomics: RET and PTEN as illustrative models. Nature Reviews. Cancer 7 35-45. (Pubitemid 46020845)
155. Ziebold U, Lee EY, Bronson RT & Lees JA 2003 E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. Molecular and Cellular Biology 23 6542-6552. (Pubitemid 37075765)